PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study
Open Access
- 2 April 2024
- journal article
- research article
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 25 (4) , 1441-1450
Abstract
Objective: Endometrial carcinoma (EC) is the most common cancer of the female genital tract. According to the recently evolved strategies of cancer immunotherapy, immune checkpoints inhibitors are one of the most crucial strategies. Programmed Death Ligand 1 (PD-L1) is an important immune checkpoint regulator. PD-L1 antibodies have shown efficacy in clinical trials of some malignancies. Some of these antibodies have been approved for clinical usage by the Food and Drug Administration (FDA). Methods: This retrospective study included a total of 100 ECs, collected from archived, formalin-fixed, paraffin-embedded tissue blocks of hysterectomy specimens of Egyptian females. The samples were immunohistochemically analyzed for PD-L1 expression (in both tumor cells; TCs and tumor infiltrating leucocytes; TILs) by a semiquantitative score (0 to 4), with cutoff points of (0: <1% of the cells, 1: 1% to 4%, 2: 5% to 9%, 3: 10% to 49%, and 4: ≥ 50%). Membranous staining only was considered positive. Results: PD-L1 was highly expressed in ECs (67% TCs+ and 61% TILs+), with statistically significant relationships with age, lympho-vascular space invasion (LVSI) and TILs score (P = 0.006, 0.016 and <0.005 respectively). However, no statistically significant relationships were detected between PD-L1 expression and the following parameters: histological type, histological grade, pathological stage (pT) or FIGO stage, myometrial, cervical, adnexal/serosal, parametrial involvements and nodal metastasis, as well as ESMO risk stratification system. Moreover, statistically significant relationships were achieved when correlating TILs score with tumor grade and LVSI (P = 0.034 and 0.012 respectively). Also, comparing endometrial hyperplasia (EH) PD-L1 and TCs PDL1 median scores achieved statistically significant relationship (P = 0.001). Conclusion: Our results concluded that PD-L1 expression was greater in both TCs and TILs in a subgroup of patients that have advanced age, LVSI and are TILs-rich, identifying them as potential candidates for anti-PD-1/PD-L1 immunotherapy.Keywords
This publication has 23 references indexed in Scilit:
- Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial CancerInternational Journal of Gynecological Pathology, 2019
- Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytesLaboratory Investigation, 2019
- Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer CenterInternational Journal of Gynecological Pathology, 2018
- Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial CancersInternational Journal of Gynecological Cancer, 2018
- Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinomaJournal of Cancer Research and Therapeutics, 2018
- Clinical Significance of PD1 and PDL1 in Human Breast CancerAnticancer Research, 2017
- Immunotherapy in Endometrial Cancer: In the Nick of TimeClinical Cancer Research, 2016
- Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancerOncology Letters, 2016
- Risk factor analysis of recurrence in low-grade endometrial adenocarcinomaHuman Pathology, 2015
- Immunotherapy in endometrial cancer - an evolving therapeutic paradigmGynecologic Oncology Research and Practice, 2015